The 2016 WHO Classification and Diagnostic Criteria for Myeloproliferative Neoplasms: Document Summary and In-depth Discussion

Overview

Journal Blood Cancer J

Date 2018 Feb 11

PMID 29426921

Citations 243

Authors

Tiziano Barbui

Jurgen Thiele

Heinz Gisslinger

Hans Michael Kvasnicka

Alessandro M Vannucchi

Paola Guglielmelli

Attilio Orazi

Ayalew Tefferi

Affiliations

Soon will be listed here.

Abstract

The new edition of the 2016 World Health Organization (WHO) classification system for tumors of the hematopoietic and lymphoid tissues was published in September 2017. Under the category of myeloproliferative neoplasms (MPNs), the revised document includes seven subcategories: chronic myeloid leukemia, chronic neutrophilic leukemia, polycythemia vera (PV), primary myelofibrosis (PMF), essential thrombocythemia (ET), chronic eosinophilic leukemia-not otherwise specified and MPN, unclassifiable (MPN-U); of note, mastocytosis is no longer classified under the MPN category. In the current review, we focus on the diagnostic criteria for JAK2/CALR/MPL mutation-related MPNs: PV, ET, and PMF. In this regard, the 2016 changes were aimed at facilitating the distinction between masked PV and JAK2-mutated ET and between prefibrotic/early and overtly fibrotic PMF. In the current communication, we (i) provide practically useful resource tables and graphs on the new diagnostic criteria including outcome, (ii) elaborate on the rationale for the 2016 changes, (iii) discuss the complementary role of mutation screening, (iv) address ongoing controversies and propose solutions, (v) attend to the challenges of applying WHO criteria in routine clinical practice, and (vi) outline future directions from the perspectives of the clinical pathologist.

Citing Articles

Visualization of Critical Limits and Critical Values Facilitates Interpretation.

Shah A, Dohner J, Cheng K, Garcia M, Kost G Diagnostics (Basel). 2025; 15(5).

PMID: 40075851 PMC: 11899349. DOI: 10.3390/diagnostics15050604.

Evolution of WHO diagnostic criteria in "Classical Myeloproliferative Neoplasms" compared with the International Consensus Classification.

Thiele J, Kvasnicka H, Gianelli U, Arber D, Tefferi A, Vannucchi A Blood Cancer J. 2025; 15(1):31.

PMID: 40038244 PMC: 11880409. DOI: 10.1038/s41408-025-01235-7.

Single nucleotide polymorphism and promoter methylation analysis of protein tyrosine phosphatase 1B in patients with myeloproliferative neoplasms.

Zhou J, Wu H, Li B, Zhou L, Zhang W, Ding Y Transl Cancer Res. 2025; 14(1):212-224.

PMID: 39974415 PMC: 11833361. DOI: 10.21037/tcr-24-1338.

High Levels of C5a Are Associated With Reduced Macular Sensitivity in Patients With Myeloproliferative Neoplasms.

Gotfredsen K, Abou-Taha A, Liisborg C, Krogh Nielsen M, Larsen M, Skov V Invest Ophthalmol Vis Sci. 2025; 66(2):41.

PMID: 39946135 PMC: 11827620. DOI: 10.1167/iovs.66.2.41.

Longitudinal association between hemoglobin and lung function with insights into the incidence of airflow obstruction: an observational study.

Kim J, Kim Y, Leem A, Jung J, Kim Y, Park Y BMC Pulm Med. 2025; 25(1):50.

PMID: 39885467 PMC: 11783840. DOI: 10.1186/s12890-025-03505-3.

References

Barosi G, Mesa R, Thiele J, Cervantes F, Campbell P, Verstovsek S . Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2007; 22(2):437-8. DOI: 10.1038/sj.leu.2404914. View

Gisslinger H, Jeryczynski G, Gisslinger B, Wolfler A, Burgstaller S, Buxhofer-Ausch V . Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria. Leukemia. 2015; 30(5):1126-32. PMC: 4858583. DOI: 10.1038/leu.2015.360. View

Barraco D, Cerquozzi S, Hanson C, Ketterling R, Pardanani A, Gangat N . Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. Blood Cancer J. 2017; 7(3):e538. PMC: 5380902. DOI: 10.1038/bcj.2017.17. View

Bain B . Bone marrow biopsy morbidity: review of 2003. J Clin Pathol. 2005; 58(4):406-8. PMC: 1770618. DOI: 10.1136/jcp.2004.022178. View

Klampfl T, Gisslinger H, Harutyunyan A, Nivarthi H, Rumi E, Milosevic J . Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369(25):2379-90. DOI: 10.1056/NEJMoa1311347. View

Lussana F, Carobbio A, Randi M, Elena C, Rumi E, Finazzi G . A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. Br J Haematol. 2014; 167(4):541-6. DOI: 10.1111/bjh.13080. View

Levine R, Wadleigh M, Cools J, Ebert B, Wernig G, Huntly B . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4):387-97. DOI: 10.1016/j.ccr.2005.03.023. View

Thiele J, Kvasnicka H . Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol. 2006; 85(4):226-32. DOI: 10.1007/s00277-005-0042-8. View

Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F . Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017; 129(24):3227-3236. DOI: 10.1182/blood-2017-01-761999. View

10.

Campbell P, Scott L, Buck G, Wheatley K, East C, Marsden J . Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005; 366(9501):1945-53. DOI: 10.1016/S0140-6736(05)67785-9. View

11.

Thiele J, Kvasnicka H . Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features--a clinicopathological study on 272 patients. Histol Histopathol. 2003; 18(1):93-102. DOI: 10.14670/HH-18.93. View

12.

Jeryczynski G, Thiele J, Gisslinger B, Wolfler A, Schalling M, Gleiss A . Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. Am J Hematol. 2017; 92(9):885-891. DOI: 10.1002/ajh.24788. View

13.

Gianelli U, Iurlo A, Cattaneo D, Lambertenghi-Deliliers G . Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. Expert Rev Hematol. 2014; 7(2):255-64. DOI: 10.1586/17474086.2014.876898. View

14.

Barbui T, Thiele J, Gisslinger H, Finazzi G, Carobbio A, Rumi E . Masked polycythemia vera (mPV): results of an international study. Am J Hematol. 2013; 89(1):52-4. DOI: 10.1002/ajh.23585. View

15.

Vener C, Fracchiolla N, Gianelli U, Calori R, Radaelli F, Iurlo A . Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood. 2007; 111(4):1862-5. DOI: 10.1182/blood-2007-09-112953. View

16.

Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour J, Ianotto J . Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2015; 127(3):333-42. DOI: 10.1182/blood-2015-07-661983. View

17.

Tefferi A, Guglielmelli P, Larson D, Finke C, Wassie E, Pieri L . Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014; 124(16):2507-13. PMC: 4199952. DOI: 10.1182/blood-2014-05-579136. View

18.

Milosevic Feenstra J, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I . Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2015; 127(3):325-32. PMC: 4752213. DOI: 10.1182/blood-2015-07-661835. View

19.

Tefferi A, Lasho T, Finke C, Elala Y, Hanson C, Ketterling R . Targeted deep sequencing in primary myelofibrosis. Blood Adv. 2018; 1(2):105-111. PMC: 5737166. DOI: 10.1182/bloodadvances.2016000208. View

20.

Madelung A, Bondo H, Stamp I, Loevgreen P, Nielsen S, Falensteen A . World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations--the Danish experience. Am J Hematol. 2013; 88(12):1012-6. DOI: 10.1002/ajh.23554. View